Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin

NCT05819125 · clinicaltrials.gov ↗

TERMINATED

Status

21000

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's decision. Termination decision unrelated to safety profile.

Conditions

Venous Thromboembolism

Sponsor

Sanofi